ClinicalTrials.gg
CompletedNCT03353350AMPLITUDE-MUpdated Jan 18, 2022Results posted

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

A Phase 3 interventional study of efpeglenatide (SAR439977) and placebo in Type 2 Diabetes Mellitus, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 54 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-18.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited — 2 open to participants now, 2 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Hanmi Pharmaceutical Company Limited.

Enrollment
Largest of 10
406 · median 102
Started
2017
with 1 other
Phase 3
2 of 10
1 open now
Registered
7th of 10
by date

Among the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited, this one has the largest enrollment, is one of 2 that started in 2017, is one of 2 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with T2DM (Type 2 Diabetes Mellitus) inadequately controlled with diet and exercise.

Secondary Objectives:

  • To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on glycemic control
  • To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on body weight
  • To evaluate the safety of once-weekly injection of efpeglenatide
Read the detailed description

Study duration per participant is approximately 65 weeks, including a 3-week screening period, 30 weeks core treatment period, 26 weeks extension treatment period, and 6 weeks safety follow up.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be at least 18 years of age at the time of signing the .
  • Participants with T2DM, and treated with diet and exercise.
  • between 7.0% and 10.0% (inclusive) measured by the central laboratory at Screening.

Exclusion criteria

Exclusion criteria:

  • history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to) gastroparesis, unstable and not controlled gastroesophageal reflux disease within 6 months prior to Screening or history of surgery affecting gastric emptying.
  • History of pancreatitis (unless pancreatitis was related to gallstone and cholecystectomy has been performed) and pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, and pancreatectomy.
  • Personal or family history of Medullary Thyroidian Cancer (MTC) or genetic conditions that predisposes to MTC (eg multiple endocrine neoplasia syndromes).
  • Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months of screening) or planned: intravitreal injections or laser or vitrectomy surgery.
  • Body weight change of ≥5 kg within the last 3 months prior to Screening.
  • Systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg at Randomization.
  • End-stage renal disease as defined by estimated (eGFR , by Modification of Diet in Renal Disease [MDRD]) of \<15 mL/min/1.73 m2.
  • Laboratory findings at the Screening Visit:
  • (ALT ) or aspartate aminotransferase (AST ) >3 times the (ULN ) or total >1.5 times the ULN (except in case of documented Gilbert's syndrome).
  • Amylase and/or lipase: >3 times the ULN laboratory range.
  • Calcitonin ≥5.9 pmol/L (20 pg/mL).
  • Gastric surgery or other gastric procedures intended for weight loss within 2 years prior to Screening, or planned during study period.
  • History of drug or alcohol abuse within 6 months prior to the time of Screening.
  • Pregnant (demonstrated by serum pregnancy test at Screening) or breast-feeding women.
  • Women of not willing to use highly effective method(s) of during the study period and for at least 5 weeks after the last dose of study intervention.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
406 participants (actual)

Study arms

  • Experimental
    Efpeglenatide 2mg

    Efpeglenatide low dose (Prefilled syringe) administered once weekly for 56 weeks

    Drug: efpeglenatide (SAR439977)

  • Experimental
    Efpeglenatide 4 mg

    Efpeglenatide middle dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)

    Drug: efpeglenatide (SAR439977)

  • Experimental
    Efpeglenatide 6 mg

    Efpeglenatide high dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)

    Drug: efpeglenatide (SAR439977)

  • Placebo comparator
    Placebo

    Matching placebo (Prefilled syringe) administered once weekly for 56 weeks

    Drug: placebo

Interventions

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • Drugplacebo

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

06

What researchers measure

Primary outcomes

  1. Change in Glycated Hemoglobin (HbA1c) (%)

    Change from Baseline to Week 30 in HbA1c

    Time frame: Baseline to Week 30

Secondary outcomes

  1. Change in HbA1c (%)

    Change from Baseline to Week 56 in HbA1c

    Time frame: Baseline to Week 56

  2. Change in Fasting Plasma Glucose (FPG)

    Change from Baseline to Week 30 in FPG

    Time frame: Baseline to Week 30

  3. HbA1c <7%

    Number of participants with HbA1c \<7.0% at Week 30

    Time frame: Week 30

  4. Change in Body Weight at Week 30

    Change from Baseline to Week 30 in body weight

    Time frame: Baseline to Week 30

  5. Change in Body Weight at Week 56

    Change from Baseline to Week 56 in body weight

    Time frame: Baseline to Week 56

  6. Hypoglycemic Participants

    Number of participants with at least 1 hypoglycemic event during treatment period

    Time frame: Baseline to Week 56

  7. Hypoglycemic Events

    Number of hypoglycemic events

    Time frame: Baseline to Week 56

  8. Treatment Emergent Adverse Events (TEAEs)

    Number of participants with TEAEs

    Time frame: Baseline to Week 56

07

Results

Posted Jan 18, 2022

Participant flow

30-week Core Treatment Period
Participant flow — 30-week Core Treatment Period
MilestonePlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Started102100101103
Completed80817781
Not completed22192422
Withdrew: Protocol violation1110
Withdrew: Other: not related to covid-192220
Withdrew: Adverse event0423
Withdrew: Withdrawal by subject19121919
26-week Treatment Extension Period
Participant flow — 26-week Treatment Extension Period
MilestonePlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Started80817781
Completed75787367
Not completed53414
Withdrew: Protocol violation2000
Withdrew: Other: not related to covid-190011
Withdrew: Adverse event1001
Withdrew: Withdrawal by subject23312

Outcome measures

PrimaryChange in Glycated Hemoglobin (HbA1c) (%)

Change from Baseline to Week 30 in HbA1c

Time frame:
Baseline to Week 30
Reported as:
Mean · HbA1c (%)
Change in Glycated Hemoglobin (HbA1c) (%)
HbA1c (%)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Change in Glycated Hemoglobin (HbA1c) (%)-0.46 ± 1.16-1.14 ± 0.96-1.48 ± 1.01-1.59 ± 1.04
SecondaryChange in HbA1c (%)

Change from Baseline to Week 56 in HbA1c

Time frame:
Baseline to Week 56
Reported as:
Mean · HbA1c (%)
Change in HbA1c (%)
HbA1c (%)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Change in HbA1c (%)-0.52 ± 1.18-1.18 ± 0.79-1.51 ± 0.99-1.51 ± 0.18
SecondaryChange in Fasting Plasma Glucose (FPG)

Change from Baseline to Week 30 in FPG

Time frame:
Baseline to Week 30
Reported as:
Mean · FPG (mmol/L)
Change in Fasting Plasma Glucose (FPG)
FPG (mmol/L)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Change in Fasting Plasma Glucose (FPG)8.59 ± 2.13-0.87 ± 3.276.84 ± 1.576.55 ± 1.30
SecondaryHbA1c <7%

Number of participants with HbA1c \<7.0% at Week 30

Time frame:
Week 30
Reported as:
Count of participants · Participants
HbA1c <7%
ParticipantsPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
HbA1c <7%26606676
SecondaryChange in Body Weight at Week 30

Change from Baseline to Week 30 in body weight

Time frame:
Baseline to Week 30
Reported as:
Mean · kg
Change in Body Weight at Week 30
kgPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Change in Body Weight at Week 30-1.35 ± 3.15-1.01 ± 3.66-3.34 ± 4.19-3.19 ± 4.77
SecondaryChange in Body Weight at Week 56

Change from Baseline to Week 56 in body weight

Time frame:
Baseline to Week 56
Reported as:
Mean · kg
Change in Body Weight at Week 56
kgPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Change in Body Weight at Week 56-1.26 ± 4.19-0.94 ± 4.96-3.24 ± 6.42-1.82 ± 5.52
SecondaryHypoglycemic Participants

Number of participants with at least 1 hypoglycemic event during treatment period

Time frame:
Baseline to Week 56
Reported as:
Count of participants · Participants
Hypoglycemic Participants
ParticipantsPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Hypoglycemic Participants2101414
SecondaryHypoglycemic Events

Number of hypoglycemic events

Time frame:
Baseline to Week 56
Reported as:
Number · Number of events
Hypoglycemic Events
Number of eventsPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Hypoglycemic Events2101414
SecondaryTreatment Emergent Adverse Events (TEAEs)

Number of participants with TEAEs

Time frame:
Baseline to Week 56
Reported as:
Number · Number of Treatment Emergent AEs
Treatment Emergent Adverse Events (TEAEs)
Number of Treatment Emergent AEsPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Treatment Emergent Adverse Events (TEAEs)79807983

Adverse events

Collected over All Adverse Events (AEs), Serious AEs (SAEs), Adverse Events of Special Interest (AESIs) and AEs requiring specific monitoring were collected from the date of signing the Informed Consent Form (ICF) until the end of the study, defined by the protocol for that participant as Week 62.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/102 (0%)9/102 (8.8%)70/102 (68.6%)
Efpeglenatide 2 mg0/102 (0%)11/102 (10.8%)69/102 (67.6%)
Efpeglenatide 4 mg0/103 (0%)6/103 (5.8%)73/103 (70.9%)
Efpeglenatide 6 mg1/99 (1%)6/99 (6.1%)77/99 (77.8%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
CystitisInfections and infestations0/1020/1020/1031/99
EpiglottitisInfections and infestations0/1020/1020/1031/99
Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1020/1020/1031/99
Laryngeal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1020/1020/1031/99
Vertebral artery stenosisNervous system disorders0/1020/1020/1031/99
Ventricular tachycardiaCardiac disorders0/1020/1020/1031/99
Myocardial infarctionCardiac disorders1/1020/1020/1031/99
GastroenteritisInfections and infestations0/1021/1020/1030/99
Meningitis viralInfections and infestations1/1020/1020/1030/99
Benign ovarian tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1021/1020/1030/99
Most frequent other events
Showing 10 of 400
Most frequent other events
EventPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
DiarrhoeaGastrointestinal disorders9/1029/10217/10325/99
NauseaGastrointestinal disorders2/1026/10215/10322/99
ConstipationGastrointestinal disorders6/1029/10214/10316/99
HeadacheNervous system disorders7/1026/10210/10315/99
DyspepsiaGastrointestinal disorders2/1025/1027/10312/99
NasopharyngitisInfections and infestations8/10210/1027/10311/99
Injection site painGeneral disorders6/1029/10211/10311/99
Decreased appetiteMetabolism and nutrition disorders2/1022/10211/1038/99
DizzinessNervous system disorders6/1022/10210/1036/99
VomitingGastrointestinal disorders0/1023/1028/1039/99

Baseline characteristics

Age, Customized
Age, Customized(Participants)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mgTotal
<502221302194
≥50 and <6543464444177
≥65 and <7526282031105
≥751157730
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mgTotal
Female51454942187
Male51555261219
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mgTotal
Race : White90938692361
Race : Black or African American10613837
Race : Asian20125
Race : Other00112
Race : Multiple01001
Ethnicity : Hispanic or Latino2020252186
Ethnicity : Not Hispanic or Latino82807682320
Region of Enrollment
Region of Enrollment(participants)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mgTotal
North America54535758222
Europe48474445184
Screening HbA1c
Screening HbA1c(%)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mgTotal
Mean7.98 ± 0.858.03 ± 0.758.14 ± 0.938.07 ± 0.918.05 ± 0.87
Baseline BMI
Baseline BMI(kg/m²)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mgTotal
Mean34.8 ± 7.134.4 ± 6.433.8 ± 6.633.8 ± 6.934.2 ± 6.8
Baseline BMI category
Baseline BMI category(Participants)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mgTotal
<3028282828112
≥30 and <4052535860223
≥402219151470
Unknown00011
08

Study locations

54 sites
  • Investigational Site Number 8400004
    Birmingham, Alabama 35205, United States
  • Investigational Site Number 8400005
    Glendale, Arizona 85306, United States
  • Investigational Site Number 8400003
    Canoga Park, California 91303, United States
  • Investigational Site Number 8400007
    Chula Vista, California 91911, United States
  • Investigational Site Number 8400011
    La Mesa, California 91942, United States
  • Investigational Site Number 8400009
    Los Angeles, California 90057, United States
  • Investigational Site Number 8400029
    Pomona, California 91767, United States
  • Investigational Site Number 8400024
    Tarzana, California 91356, United States
  • Investigational Site Number 8400026
    Van Nuys, California 91405, United States
  • Investigational Site Number 8400010
    DeLand, Florida 32720, United States
  • Investigational Site Number 8400006
    Hialeah, Florida 33012, United States
  • Investigational Site Number 8400032
    West Palm Beach, Florida 33409, United States
  • Investigational Site Number 8400025
    Lawrenceville, Georgia 30044, United States
  • Investigational Site Number 8400034
    Chicago, Illinois 60612, United States
  • Investigational Site Number 8400033
    Kansas City, Missouri 64128, United States
  • Investigational Site Number 8400018
    Lincoln, Nebraska 68503, United States
  • Investigational Site Number 8400062
    Las Vegas, Nevada 89106, United States
  • Investigational Site Number 8400021
    Las Vegas, Nevada 89109, United States
  • Investigational Site Number 8400001
    Bridgeton, New Jersey 08302, United States
  • Investigational Site Number 8400028
    Burlington, North Carolina 27215, United States
  • Investigational Site Number 8400031
    Wilmington, North Carolina 28401, United States
  • Investigational Site Number 8400013
    Maumee, Ohio 43537, United States
  • Investigational Site Number 8400008
    Hatboro, Pennsylvania 19040, United States
  • Investigational Site Number 8400017
    Carrollton, Texas 75010, United States
  • Investigational Site Number 8400030
    Dallas, Texas 75230, United States
  • Investigational Site Number 8400015
    Houston, Texas 77074, United States
  • Investigational Site Number 8400019
    Plano, Texas 75024, United States
  • Investigational Site Number 8400020
    San Antonio, Texas 78218, United States
  • Investigational Site Number 8400016
    San Antonio, Texas 78229, United States
  • Investigational Site Number 8400027
    San Antonio, Texas 78229, United States
  • Investigational Site Number 8400023
    Schertz, Texas 78154, United States
  • Investigational Site Number 8400002
    Holladay, Utah 84117-7054, United States
  • Investigational Site Number 2760005
    Berlin, 12627, Germany
  • Investigational Site Number 2760003
    Frankfurt Am Main, 60313, Germany
  • Investigational Site Number 2760001
    Leipzig, 04103, Germany
  • Investigational Site Number 6160005
    Gdansk, 80-382, Poland
  • Investigational Site Number 6160004
    Gdynia, 81-537, Poland
  • Investigational Site Number 6160007
    Katowice, 40-040, Poland
  • Investigational Site Number 6160002
    Krakow, 31-501, Poland
  • Investigational Site Number 6160006
    Poznan, 60-702, Poland
  • Investigational Site Number 6160003
    Warszawa, 01-192, Poland
  • Investigational Site Number 6160001
    Wroclaw, 50-381, Poland
  • Investigational Site Number 8040003
    Kyiv, 02002, Ukraine
  • Investigational Site Number 8040001
    Kyiv, 03037, Ukraine
  • Investigational Site Number 8040002
    Kyiv, 03049, Ukraine
  • Investigational Site Number 8040004
    Vinnitsa, 21009, Ukraine
  • Investigational Site Number 8260005
    Birmingham, B15 2SQ, United Kingdom
  • Investigational Site Number 8260004
    Cardiff, CF15 9SS, United Kingdom
  • Investigational Site Number 8260007
    Chorley, PR7 7NA, United Kingdom
  • Investigational Site Number 8260008
    Glasgow, G20 0SP, United Kingdom
  • Investigational Site Number 8260001
    Hexham, NE46 1QJ, United Kingdom
  • Investigational Site Number 8260003
    Liverpool, L22 0LG, United Kingdom
  • Investigational Site Number 8260006
    Manchester, M15 6SX, United Kingdom
  • Investigational Site Number 8260002
    Reading, RG2 0TG, United Kingdom
09

References and documents

Publications

  • Frias JP, Choi J, Rosenstock J, Popescu L, Niemoeller E, Muehlen-Bartmer I, Baek S. Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial. Diabetes Care. 2022 Jul 7;45(7):1592-1600. doi: 10.2337/dc21-2656. PubMed 35671039 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jan 2020, 25 months.

Results were first posted in Jan 2022, 1 year 11 months after primary completion. A results delay was requested in Jan 2021.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 25 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2017
First posted
Nov 27, 2017
StartActual
Dec 5, 2017
Primary completionActual
Jan 29, 2020
CompletionActual
Sep 7, 2020
Results delay requested
Jan 26, 2021
Results first posted
Jan 18, 2022
Last update
Jan 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03353350
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 27, 2017
Start date
Dec 5, 2017
Primary completion
Jan 29, 2020
Completion
Sep 7, 2020
Results posted
Jan 18, 2022
Last update
Jan 18, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efpeglenatide

Start the discussion